AIM: To observe the clinical effect of intravitreal injection of ranibizumab combined with vitrectomy in the treatment of proliferative diabetic retinopathy(PDR).

METHODS: A retrospective study. Sixty patients(66 eyes)with PDR who underwent vitrectomy in our hospital from May 2016 to May 2017 were divided into two groups according to different treatment methods, 30 cases(33 eyes). ranibizumab were injected into vitreous cavity 3-5d before operation in group A, but not in group B. The incidence of iatrogenic retinal holes, intravitreal hemorrhage, visual acuity and complications were compared between the two groups.

RESULTS:Iatrogenic retinal hiatus and intravitreal hemorrhage occurred in both groups during operation. The number of eyes with iatrogenic retinal hiatus and the incidence of intravitreal hemorrhage in group A were less than those in group B(P<0.05). The visual acuity of group A was better than that of group B(P<0.05). After operation, the number of eyes with intravitreal hemorrhage, high intraocular pressure and macular edema in group A was less than that in group B(P<0.05).

CONCLUSION: Preoperative intravitreal injection of ranibizumab combined with vitrectomy for PDR can effectively reduce iatrogenic retinal hiatus and intravitreal hemorrhage. Postoperative complications are less, which is conducive to the recovery of patients.